Plasmology4

03/18/2025

Plasmology4 Investment Closing Webinar
March 19th @ noon ET

Register here: https://us02web.zoom.us/webinar/register/WN_3MYCoNgrRfyrGvU8OXDVnw

CEO Robert Hummel will be hosting a Webinar to answer questions and share “electrifying” details about Plasmology4’s transformative technology…Plaz4!! This is your chance to ask any question(s) you might have about this exciting company and their future plans.

01/27/2025

An important part of Plasmology4’s business strategy is to create new intellectual property in the form of patents, know-how, and trade secrets.

An important part of Plasmology4’s business strategy is to create new intellectual property, in the form of patents, know-how and trade secrets.   

01/14/2025

Plasmology4 is pioneering a new category of plasma called Plaz4, which has many of the same characteristics as a natural hot plasma, but is completely non-thermal and cool to the touch (~80º F). We believe Plaz4 technology offers a unique therapeutic energy that effectively targets pathogens while remaining safe for human cells and tissues. Watch the video for more details.

A short video describing Plaz4, Plasmology4's non-thermal plasma technology.

01/13/2025

We're thrilled to announce that Plasmology4 has been spotlighted in Healthcare Brew, a leading newsletter renowned for its insights into pharmaceutical advancements, innovative healthcare startups, and the latest breakthroughs in medical technology.

The featured article delves into the company’s pioneering first product, which holds the promise of addressing the critical issue of antibiotic-resistant wounds worldwide. It also emphasizes the tremendous market potential (exceeding $100 billion) for our groundbreaking Plaz4 technology platform.

You can read the full article here: https://www.healthcare-brew.com/issues/provider-predictions

Stay connected for more exciting updates from Plasmology4!

12/06/2024

Join us, as we mark the 10th annual World AMR Awareness Week. This pivotal global initiative sheds light on the escalating threat of antimicrobial resistance, a challenge where bacteria and fungi are increasingly outsmarting current treatments, leaving infections more difficult, and at times, impossible to treat.

At the forefront of innovation, Plasmology4 is developing Plaz4, which aims to be a drug-free solution for addressing antibiotic-resistant bacteria in wounds. Extensive in vitro and in vivo studies suggest that Plaz4 has shown promise in potentially reducing resistant pathogens and may contribute to improved wound healing.

We encourage you to stand with us in raising awareness and driving action against the global AMR crisis. Together, we can forge a path toward effective solutions and improved outcomes.

11/15/2024

Plasmology4 Secures Two New U.S. Patents, Strengthening Its Innovative Edge

Plasmology4 is proud to announce the addition of two newly issued U.S. patents, expanding our patent portfolio and reinforcing our commitment to innovation. With these latest additions, our total issued patent count rises to 47, including 36 U.S. patents and 11 international patents, underscoring our leadership in the non-thermal plasma field.

The first of these, U.S. Patent No. 12,137,513, broadens the scope of our Plaz4 technology by introducing novel device and method claims. These advancements in patent protection may enable further development of our proprietary Harmonic RF energy generation technology, which we anticipate could protect our newest delivery configurations with potential applications across healthcare products and possibly into non-healthcare domains

On the subject of non-healthcare applications of Plaz4…U.S. Patent No. 11,684,018 unveils innovative claims covering groundbreaking methods and systems for generating plasma-activated liquids or gases, with a focus on agricultural applications. This is our second patent in the agricultural sector, reflecting our belief in this field’s potential as a dynamic vertical for Plasmology4, based on our strategic assessments. While healthcare remains our current and primary focus, we are excited by the possibilities that lie in leveraging our technology for transformative agricultural solutions.

Plasmology4 remains committed to executing an intellectual property strategy aimed at securing exclusive rights, offering legal protection, and potentially providing a competitive advantage. Our continued investment in patent development is intended to enhance the company’s value and affirms our dedication to pioneering advancements in a strategic array of industries

Stay tuned as we continue to explore and expand the potential of our patented technologies.

10/28/2024

https://www.startengine.com/offering/plasmology4

Plasmology4 is on the verge of major milestones, as we begin the final product certification testing necessary for upcoming pre-clinical studies, human clinical trials and eventual FDA approval. These critical phases require additional capital to ensure we execute our strategy effectively and efficiently.

To support this effort, we just launched a Regulation CF equity offering and thrilled to share that we have been accepted by StartEngine, a leading fintech platform for equity fundraising, to facilitate this initiative. To join us on this exciting journey, you can explore our offering details at the Plasmology4 campaign page hosted on StartEngine.

A Revolutionary Technology for Healthcare

02/12/2020

FDA Grants Plasmology4® "Breakthrough Device Designation" for the Treatment of Multidrug-Refractory Bacteria.

https://www.prnewswire.com/news-releases/fda-grants-plasmology4-breakthrough-device-designation-for-the-treatment-of-multidrug-refractory-bacteria-301003388.html

/PRNewswire/ -- Plasmology4®, Inc., a leader in Plasma Medicine, announced that the company's product has been granted into the U.S. Food and Drug...